| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| D J P David, M Bourin, G Jego, C Przybylski, P Jolliet, A M Gardie. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. British journal of pharmacology. vol 140. issue 6. 2004-08-17. PMID:14530210. |
in vivo, paroxetine induced similar increases in cortical [5-ht]ext at the three doses tested, and induced a statistically significant increase in cortical [na]ext at 4 and 8 mg x kg-1. |
2004-08-17 |
2023-08-12 |
mouse |
| D J P David, M Bourin, G Jego, C Przybylski, P Jolliet, A M Gardie. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. British journal of pharmacology. vol 140. issue 6. 2004-08-17. PMID:14530210. |
citalopram and paroxetine have the highest potency to increase cortical [5-ht]ext and [na]ext, respectively. |
2004-08-17 |
2023-08-12 |
mouse |
| D J P David, M Bourin, G Jego, C Przybylski, P Jolliet, A M Gardie. Effects of acute treatment with paroxetine, citalopram and venlafaxine in vivo on noradrenaline and serotonin outflow: a microdialysis study in Swiss mice. British journal of pharmacology. vol 140. issue 6. 2004-08-17. PMID:14530210. |
in addition, the rank of order of efficacy of these antidepressant drugs to increase [5-ht]ext in vivo in the fcx of mice was as follows: venlafaxine>citalopram>paroxetine, while the efficacy to increase cortical [na]ext in mice of paroxetine and citalopram is similar, and greater than that of venlafaxine. |
2004-08-17 |
2023-08-12 |
mouse |
| David Cohen, Priscille Gerardin, Philippe Mazet, Diane Purper-Ouakil, Martine F Flamen. Pharmacological treatment of adolescent major depression. Journal of child and adolescent psychopharmacology. vol 14. issue 1. 2004-08-17. PMID:15142388. |
seven studies, including a total of 1,403 patients, evaluated the efficacy of three specific serotonin reuptake inhibitors: fluoxetine, paroxetine, and sertraline. |
2004-08-17 |
2023-08-12 |
Not clear |
| David Cohen, Priscille Gerardin, Philippe Mazet, Diane Purper-Ouakil, Martine F Flamen. Pharmacological treatment of adolescent major depression. Journal of child and adolescent psychopharmacology. vol 14. issue 1. 2004-08-17. PMID:15142388. |
based on published data, serotonin reuptake inhibitors appear to be the first-line psychopharmacologic treatment for adolescent depression, as three compounds (fluoxetine, paroxetine, and sertraline) appeared to be effective in this indication. |
2004-08-17 |
2023-08-12 |
Not clear |
| Anna-Carin Wihlbäck, Inger Sundström Poromaa, Marie Bixo, Per Allard, Tom Mjörndal, Olav Spigse. Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding. Psychoneuroendocrinology. vol 29. issue 6. 2004-07-22. PMID:15110925. |
given these facts, the purpose of this study was to examine whether binding of [3h]paroxetine to the platelet serotonin transporter or binding of [3h]lysergic acid diethylamide ([3h]lsd) to the platelet 5-ht2a receptor are influenced by the cyclical changes in circulating estradiol and progesterone that occur during the menstrual cycle. |
2004-07-22 |
2023-08-12 |
Not clear |
| Kim Brøse. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie. vol 59. issue 1. 2004-07-21. PMID:15199661. |
the five selective serotonin reuptake inhibitors, citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline are also oxidised by the cyp enzyme system. |
2004-07-21 |
2023-08-12 |
human |
| Liliana Dell'Osso, Claudia Carmassi, Lionella Palego, Maria Letizia Trincavelli, Daniela Tuscano, Marina Montali, Simone Sbrana, Antonio Ciapparelli, Antonio Lucacchini, Giovanni Battista Cassano, Claudia Martin. Serotonin-mediated cyclic AMP inhibitory pathway in platelets of patients affected by panic disorder. Neuropsychobiology. vol 50. issue 1. 2004-07-13. PMID:15179017. |
one month of treatment with paroxetine induced a significant increase of 5-ht potency in t1 patients close to the control values. |
2004-07-13 |
2023-08-12 |
human |
| Liliana Dell'Osso, Claudia Carmassi, Lionella Palego, Maria Letizia Trincavelli, Daniela Tuscano, Marina Montali, Simone Sbrana, Antonio Ciapparelli, Antonio Lucacchini, Giovanni Battista Cassano, Claudia Martin. Serotonin-mediated cyclic AMP inhibitory pathway in platelets of patients affected by panic disorder. Neuropsychobiology. vol 50. issue 1. 2004-07-13. PMID:15179017. |
these findings demonstrated that (1) a reduction of the inhibitory ac pathway activated by 5-ht occurred in platelets from pd patients; (2) the reduced 5-ht responsiveness in pd was related to an impairment of 5-ht receptor-g protein coupling, and (3) after 1 month of treatment with paroxetine, such a dysfunction significantly reversed together with a significant improvement of clinical symptoms. |
2004-07-13 |
2023-08-12 |
human |
| John F Cryan, Olivia F O'Leary, Sung-Ha Jin, Julie C Friedland, Ming Ouyang, Bradford R Hirsch, Michelle E Page, Ashutosh Dalvi, Steven A Thomas, Irwin Luck. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proceedings of the National Academy of Sciences of the United States of America. vol 101. issue 21. 2004-07-09. PMID:15148402. |
surprisingly, the effects of the selective serotonin reuptake inhibitors (ssris) fluoxetine, sertraline, and paroxetine were also absent or severely attenuated in the dbh(-/-) mice. |
2004-07-09 |
2023-08-12 |
mouse |
| F J Mackay, N R Dunn, L V Wilton, G L Pearce, S N Freemantle, R D Man. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiology and drug safety. vol 6. issue 4. 2004-06-30. PMID:15073774. |
to compare the safety and side-effect profiles of the four selective serotonin reuptake inhibitor antidepressants (ssris), fluvoxamine, fluoxetine, sertraline and paroxetine. |
2004-06-30 |
2023-08-12 |
Not clear |
| Zhuo Chen, Kate Waimey, Louis D Van de Kar, Gonzalo A Carrasco, Michelle Landry, George Battagli. Prenatal cocaine exposure potentiates paroxetine-induced desensitization of 5-HT2A receptor function in adult male rat offspring. Neuropharmacology. vol 46. issue 7. 2004-06-29. PMID:15081791. |
in contrast, paroxetine treatment reduced cortical 5-ht(2a) receptors (18-25%) and desensitized 5-ht(2a) receptor-mediated oxytocin responses in both offspring groups. |
2004-06-29 |
2023-08-12 |
rat |
| Zhuo Chen, Kate Waimey, Louis D Van de Kar, Gonzalo A Carrasco, Michelle Landry, George Battagli. Prenatal cocaine exposure potentiates paroxetine-induced desensitization of 5-HT2A receptor function in adult male rat offspring. Neuropharmacology. vol 46. issue 7. 2004-06-29. PMID:15081791. |
furthermore, in cocaine offspring, paroxetine produced an inhibition of 5-ht(2a) receptor-mediated increase in plasma acth levels and a greater attenuation of the oxytocin responses to (-)doi. |
2004-06-29 |
2023-08-12 |
rat |
| Ersin Yaris, Murat Kesim, Mine Kadioglu, Nuri Ihsan Kalyoncu, Cunay Ulku, Rasin Ozyavu. The effects of paroxetine on rat isolated vas deferens. Pharmacological research. vol 48. issue 4. 2004-06-16. PMID:12902204. |
the aim of the present study is to evaluate whether paroxetine (a selective serotonin re-uptake inhibitor) can modify the contractile responses of isolated vas deferens. |
2004-06-16 |
2023-08-12 |
rat |
| Riccardo Ponzone, Nicoletta Biglia, Piero Sismond. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute. vol 96. issue 11. 2004-06-15. PMID:15173274. |
re: active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. |
2004-06-15 |
2023-08-12 |
Not clear |
| Brooke Ratliff, Eric C Dietze, Gregory R Bean, Cassandra Moore, Sam Wanko, Victoria L Seewald. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute. vol 96. issue 11. 2004-06-15. PMID:15173275. |
re: active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. |
2004-06-15 |
2023-08-12 |
Not clear |
| Ernst A Lien, Per M Ueland, Per E Lønnin. Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. Journal of the National Cancer Institute. vol 96. issue 11. 2004-06-15. PMID:15173277. |
re: active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. |
2004-06-15 |
2023-08-12 |
Not clear |
| Albert Adel. Antidepressant properties of substance P antagonists: relationship to monoaminergic mechanisms? Current drug targets. CNS and neurological disorders. vol 3. issue 2. 2004-06-10. PMID:15078186. |
recently, a nk(1) receptor antagonist has been shown to display antidepressant activity comparable to that of the selective serotonin reuptake inhibitor paroxetine, but with a better side effect profile. |
2004-06-10 |
2023-08-12 |
mouse |
| Takehito Sawamura, Kunio Shimizu, Masashi Nibuya, Tomoki Wakizono, Go Suzuki, Tomoya Tsunoda, Yoshitomo Takahashi, Soichiro Nomur. Effect of paroxetine on a model of posttraumatic stress disorder in rats. Neuroscience letters. vol 357. issue 1. 2004-06-03. PMID:15036608. |
with or without paroxetine (prx; belonging to selective serotonin reuptake inhibitors) treatment for 2 weeks after is, we performed an avoidance/escape task session in the shuttle-box using signal lights as non-specific anxiogenic stimulants. |
2004-06-03 |
2023-08-12 |
rat |
| Jeffrey H Meyer, Alan A Wilson, Sandra Sagrati, Doug Hussey, Anna Carella, William Z Potter, Nathalie Ginovart, Edgar P Spencer, Andy Cheok, Sylvain Houl. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. The American journal of psychiatry. vol 161. issue 5. 2004-06-03. PMID:15121647. |
minimum therapeutic doses of paroxetine and citalopram produce 80% occupancy for the serotonin (5-ht) transporter (5-htt). |
2004-06-03 |
2023-08-12 |
Not clear |